CP and metabolic disease: These costs can be reduced by focusing on key proteins that may serve as biomarkers of physiological function and potentially forecast future population decline, such as those related to pregnancy and pregnancy associated disorders (ceruloplasmin and serpin B5), metabolic disease (adiponectin and alpha-1-acid glycoprotein), and stress/immune function (complement C3).